Intrathecal trastuzumab: dose matters

Author： Hofer Silvia   Mengele Karin   Stemmler Hans Joachim   Schmitt Manfred   Pestalozzi Bernhard  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.51, Iss.7, 2012-09, pp. : 955-956

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis

By Zagouri Flora  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 13-22

Springer Publishing Company

Access to resources Recommend Favorite

Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases

By Martens Jennifer  

Acta Oncologica, Vol. 52, Iss. 1, 2013-01 ,pp. : 175-178

Informa Healthcare

Access to resources Recommend Favorite

Combination of low-dose (0.1 mg) intrathecal morphine and patient-controlled intravenous morphine in the management of postoperative pain following abdominal hysterectomy

By Togal Turkan   Demirbilek Semra   Gulhas Nurcin   Koroglu Ahmet  

The Pain Clinic, Vol. 16, Iss. 3, 2004-08 ,pp. : 335-341

Maney Publishing

Access to resources Recommend Favorite

Trastuzumab Monotherapy

By Vogel Charles  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 67-68

Springer Publishing Company

Access to resources Recommend Favorite

New Agents for Intrathecal Administration

By Stapleton Stacie   Blaney Susan  

Cancer Investigation, Vol. 24, Iss. 5, 2006-06 ,pp. : 528-534

Informa Healthcare

Access to resources Recommend Favorite